A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 12 Weeks Treatment With Vildagliptin to Placebo as Add-on Therapy to Sulfonylurea in Patients With Type 2 Diabetes Inadequately Controlled With Sulfonylurea Monotherapy
Latest Information Update: 20 May 2016
At a glance
- Drugs Vildagliptin (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novartis
- 23 Nov 2006 Status change from Recruiting to In Progress
- 12 Nov 2006 New trial record.